IMNM News and Press, Immunome Inc. From 02/14/24

2024-02-14 08:38:21 ET More on Pre-market losers & stocks. Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Esports Entertainment announces 1-for-400 reverse stock split Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals His...

2024-02-14 02:35:15 ET More on Immunome Immunome: Why It Has Doubled Over The Last Month Immunome announces underwritten public offering of common stock Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors Seeking Alpha’s Quant Rating...

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of...

2024-02-13 16:33:27 ET More on Immunome Immunome: Why It Has Doubled Over The Last Month Immunome announces underwritten public offering of common stock Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors Read the full article on Seeking ...

2024-02-13 16:11:02 ET More on Immunome Immunome: Why It Has Doubled Over The Last Month Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors Immunome a new outperform at Wedbush on cancer platforms Seeking Alpha’s Quant Rating on Imm...

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $2...

2024-02-10 09:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 30.8% to $21.87 on volume of 421,271,485 shares InVivo Therapeutics Holdings Corp. (NVIV) rose 136.9% to $0.526 on volume of 188,439,590 shares New York Community Bancorp Inc. (NYCB) fell...

2024-02-06 08:14:45 ET More on Advaxis, Immunome, etc. Immunome: Why It Has Doubled Over The Last Month Immunome a new outperform at Wedbush on cancer platforms Historical earnings data for Advaxis Financial information for Advaxis Seeking Alphaȁ...

– AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into...